Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Transcatheter Arterial Chemoembolization Combined With Lenvatinib and Sintilimab for Unresectable Advanced Hepatocellular Carcinoma: An Open-label, Single-arm, Single-center, Prospective Study

NCT04599790 is registered in ClinicalTrials.gov with Second Affiliated Hospital of Guangzhou Medical University as lead sponsor.

NCT NCT04599790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04599790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Transcatheter Arterial Chemoembolization Combined With Lenvatinib and Sintilimab for Unresectable Advanced Hepatocellular Carcinoma: An Open-label, Single-arm, Single-center, Prospective Study
Lead sponsor
Second Affiliated Hospital of Guangzhou Medical University
Phase
Phase 2
Overall status
Completed
Start date
October 1, 2020
Completion date
October 31, 2022
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma non-resectable